DFDA

Pembrolizumab (Immunotherapy)

Treatment for Lip And Oral Cavity Cancer

Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks

Effectiveness
75%
Safety Score
60%
Clinical Trials
2
Participants
40K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
Weeks to months
Treatment Duration
Every 3 or 6 weeks, until progression or toxicity
Evidence Quality
HIGH
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$15,000
Side Effect Mgmt:$8,000
Total Annual:$203,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$350,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$580,000
Cost per Remission
$2,537,500
Comparison vs Chemotherapy (e.g., EXTREME regimen)
Cost Difference
+$170,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (Immunotherapy) Outcomes

for Lip And Oral Cavity Cancer

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+35%
Remission Rate
+8%
Common Side Effects
Fatigue
+25%
Rash
+15%
Pruritus
+12%
Hypothyroidism
+8%
Immune-related colitis
+3%

Sources:

onclive.com
ascopubs.org
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Pembrolizumab (Immunotherapy) in Lip And Oral Cavity Cancer

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228RECRUITINGPHASE1, PHASE2
View Study
242 participants
INTERVENTIONAL
Santa Rosa, United States +14 more
Started: Jun 8, 2018

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

NCT05172258ACTIVE NOT RECRUITINGPHASE2
View Study
52 participants
INTERVENTIONAL
Duarte, United States +19 more
Started: Jul 26, 2022

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05721755RECRUITINGPHASE3
View Study
290 participants
INTERVENTIONAL
Tampa, United States +50 more
Started: Jun 8, 2023